Buscar
Mostrando ítems 31-40 de 592
Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy
(Elsevier Inc, 2013-10)
Tyrosine kinase inhibitors (TKIs), imatinib, nilotinib and dasatinib, are the current treatment of chronic myeloid leukemia (CML). BCR-ABL1 point mutations are the principal cause of resistance to treatment; however other ...
Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance
(Associação Brasileira de Hematologia e Hemoterapia e daSociedade Brasileira de Transplante de Medula ÓsseaBrasil, 2011)
Epithelial cells treated with genistein inhibit adhesion and endocytosis of Paracoccidioides brasiliensis
(Springer, 2007-07-01)
Paracoccidioidomycosis is caused by Paracoccidioides brasiliensis, which although not formally considered an intracellular pathogen, can be internalized by epithelial cells in vitro and in vivo. The mechanisms used by P. ...
Epithelial cells treated with genistein inhibit adhesion and endocytosis of Paracoccidioides brasiliensis
(Springer, 2007-07-01)
Paracoccidioidomycosis is caused by Paracoccidioides brasiliensis, which although not formally considered an intracellular pathogen, can be internalized by epithelial cells in vitro and in vivo. The mechanisms used by P. ...
BCR-ABL binds to IRS-1 and IRS-1 phosphorylation is inhibited by imatinib in K562 cells
(Elsevier Science BvAmsterdamHolanda, 2003)
Os inibidores de tirosino quinase de segunda geração
(Associação Brasileira de Hematologia e Hemoterapia e daSociedade Brasileira de Transplante de Medula Óssea, 2008)
O imatinibe tem sido confirmado como terapia de primeira linha para a Leucemia Mielóide Crônica (LMC) por apresentar respostas duradouras na maior parte dos pacientes, principalmente nos que se encontram em fase precoce ...
Differential effects of flavonoids on bovine kidney low molecular mass protein tyrosine phosphatase
(Taylor & Francis LtdAbingdonInglaterra, 2006)